Wanbury Limited confirmed on July 30, 2026, that it has received no Drug Master File (DMF) deficiency letters from the United States Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs). This regulatory clearance specifically pertains to ANDAs utilizing Wanbury’s Metformin Hydrochloride (HCl) Active Pharmaceutical Ingredient (API) across various formulations. The absence of deficiencies reinforces the company’s compliance standing with the USFDA, a critical factor for maintaining market access for its generic drug supplies.

USFDA Regulatory Compliance

The company disclosed this update in accordance with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR). The confirmation of no DMF issues is significant for stakeholders, as DMFs contain confidential technical data regarding the manufacturing, processing, and quality control of drug substances. A clean regulatory record facilitates the approval and continued marketing of generic medicines in the United States, which remains a key revenue driver for Indian pharmaceutical exporters.

South Korea API Expansion

In parallel with its US regulatory updates, Wanbury is actively expanding its international footprint by exploring new business opportunities in South Korea. The company has filed a new DMF for an additional API to supply this emerging market. This strategic move aims to diversify its customer base and strengthen its position in the global API supply chain. Management emphasized its commitment to supplying high-quality APIs to support human well-being in these new markets.

What the Numbers Show

The dual focus on maintaining strict compliance in the mature US market while aggressively pursuing entry into South Korea highlights Wanbury’s balanced growth strategy. By securing regulatory clarity for its Metformin HCl API — a widely used medication for diabetes management — the company mitigates supply chain risks associated with regulatory holds. Simultaneously, the expansion into South Korea indicates a proactive approach to capturing demand in Asia-Pacific markets, reducing dependency on any single geographic region for its API revenues.

Wanbury 's manufacturing facility at Tanuku has received USFDA Form 483 with 6 observations from the United States Food and Drug Administration (USFDA) following a Current Good Manufacturing Practice (CGMP) inspection. The company has formally acknowledged the observations and confirmed that it will submit its response to the regulatory authority within the stipulated timeframe.

USFDA CGMP Inspection Outcome

The USFDA conducted a CGMP inspection at Wanbury's Tanuku facility, culminating in the issuance of Form 483 with 6 observations. CGMP inspections are a standard regulatory process undertaken by the USFDA to assess whether pharmaceutical manufacturing facilities comply with the required quality and safety standards for products intended for the US market. Form 483 is issued by the USFDA when an investigator observes conditions that may constitute violations of the Food Drug and Cosmetic Act during an inspection.

The key details of the regulatory development are summarised below:

Company's Response Commitment

Wanbury has stated that it will respond to the 6 observations within the timeframe provided by the USFDA. Timely and comprehensive responses to USFDA Form 483 observations are a critical step in the regulatory compliance process for pharmaceutical companies seeking to maintain or obtain approvals for the US market. The company's commitment to addressing the observations within the prescribed period reflects its engagement with the regulatory process.